nodes	percent_of_prediction	percent_of_DWPC	metapath
Metoclopramide—CYP17A1—Androgen biosynthesis—HSD17B12—peripheral nervous system neoplasm	0.0334	0.153	CbGpPWpGaD
Metoclopramide—CYP11B2—Metabolism of steroid hormones and vitamin D—HSD17B12—peripheral nervous system neoplasm	0.0172	0.0791	CbGpPWpGaD
Metoclopramide—HTR3A—vagus nerve—peripheral nervous system neoplasm	0.0155	0.267	CbGeAlD
Metoclopramide—CYP11B1—Metabolism of steroid hormones and vitamin D—HSD17B12—peripheral nervous system neoplasm	0.0148	0.0681	CbGpPWpGaD
Metoclopramide—CYP17A1—Metabolism of steroid hormones and vitamin D—HSD17B12—peripheral nervous system neoplasm	0.0139	0.0637	CbGpPWpGaD
Metoclopramide—HTR3A—cranial nerve—peripheral nervous system neoplasm	0.0118	0.203	CbGeAlD
Metoclopramide—HTR4—Serotonin Receptor 4/6/7 and NR3C Signaling—GNAS—peripheral nervous system neoplasm	0.0102	0.0467	CbGpPWpGaD
Metoclopramide—CYP11B2—ACE Inhibitor Pathway—KNG1—peripheral nervous system neoplasm	0.00949	0.0437	CbGpPWpGaD
Metoclopramide—DRD3—GPCRs, Other—ADGRV1—peripheral nervous system neoplasm	0.00856	0.0394	CbGpPWpGaD
Metoclopramide—Sunitinib—CHEK2—peripheral nervous system neoplasm	0.00702	0.178	CrCbGaD
Metoclopramide—HTR3A—SIDS Susceptibility Pathways—PHOX2B—peripheral nervous system neoplasm	0.00641	0.0295	CbGpPWpGaD
Metoclopramide—Sunitinib—ALK—peripheral nervous system neoplasm	0.00625	0.158	CrCbGaD
Metoclopramide—Sunitinib—NTRK1—peripheral nervous system neoplasm	0.00608	0.154	CrCbGaD
Metoclopramide—HTR3A—nerve—peripheral nervous system neoplasm	0.00606	0.104	CbGeAlD
Metoclopramide—HTR3A—ganglion—peripheral nervous system neoplasm	0.00599	0.103	CbGeAlD
Metoclopramide—Oxybuprocaine—BCHE—peripheral nervous system neoplasm	0.00463	0.117	CrCbGaD
Metoclopramide—HTR4—G alpha (s) signalling events—VIP—peripheral nervous system neoplasm	0.00437	0.0201	CbGpPWpGaD
Metoclopramide—Chloroprocaine—BCHE—peripheral nervous system neoplasm	0.0043	0.109	CrCbGaD
Metoclopramide—DRD3—Nicotine Activity on Dopaminergic Neurons—TH—peripheral nervous system neoplasm	0.00419	0.0193	CbGpPWpGaD
Metoclopramide—Procaine—BCHE—peripheral nervous system neoplasm	0.00411	0.104	CrCbGaD
Metoclopramide—Cinchocaine—BCHE—peripheral nervous system neoplasm	0.00411	0.104	CrCbGaD
Metoclopramide—DRD2—nerve—peripheral nervous system neoplasm	0.00371	0.0637	CbGeAlD
Metoclopramide—DRD2—ganglion—peripheral nervous system neoplasm	0.00366	0.0629	CbGeAlD
Metoclopramide—CYP2D6—Codeine and Morphine Metabolism—ABCB1—peripheral nervous system neoplasm	0.00324	0.0149	CbGpPWpGaD
Metoclopramide—DRD2—Nicotine Activity on Dopaminergic Neurons—TH—peripheral nervous system neoplasm	0.00321	0.0148	CbGpPWpGaD
Metoclopramide—HTR3A—trigeminal ganglion—peripheral nervous system neoplasm	0.00294	0.0505	CbGeAlD
Metoclopramide—HTR4—Class A/1 (Rhodopsin-like receptors)—NTS—peripheral nervous system neoplasm	0.00275	0.0126	CbGpPWpGaD
Metoclopramide—HTR3A—brainstem—peripheral nervous system neoplasm	0.0026	0.0447	CbGeAlD
Metoclopramide—HTR4—G alpha (s) signalling events—GNAS—peripheral nervous system neoplasm	0.00226	0.0104	CbGpPWpGaD
Metoclopramide—Procainamide—BCHE—peripheral nervous system neoplasm	0.00213	0.0538	CrCbGaD
Metoclopramide—CHRM1—parotid gland—peripheral nervous system neoplasm	0.00211	0.0362	CbGeAlD
Metoclopramide—HTR4—GPCR ligand binding—NTS—peripheral nervous system neoplasm	0.00209	0.00962	CbGpPWpGaD
Metoclopramide—HTR4—GPCR ligand binding—CD55—peripheral nervous system neoplasm	0.00201	0.00923	CbGpPWpGaD
Metoclopramide—CYP11B1—Corticotropin-releasing hormone—GNAS—peripheral nervous system neoplasm	0.00185	0.00852	CbGpPWpGaD
Metoclopramide—HTR3A—SIDS Susceptibility Pathways—NTRK2—peripheral nervous system neoplasm	0.00184	0.00848	CbGpPWpGaD
Metoclopramide—CYP11B2—Metabolism of lipids and lipoproteins—HSD17B12—peripheral nervous system neoplasm	0.00176	0.0081	CbGpPWpGaD
Metoclopramide—Oedema—Isotretinoin—peripheral nervous system neoplasm	0.00174	0.00254	CcSEcCtD
Metoclopramide—Oedema—Tretinoin—peripheral nervous system neoplasm	0.00174	0.00254	CcSEcCtD
Metoclopramide—Delirium—Doxorubicin—peripheral nervous system neoplasm	0.00174	0.00254	CcSEcCtD
Metoclopramide—Flushing—Alitretinoin—peripheral nervous system neoplasm	0.00173	0.00252	CcSEcCtD
Metoclopramide—Dyskinesia—Epirubicin—peripheral nervous system neoplasm	0.00172	0.00252	CcSEcCtD
Metoclopramide—Oedema—Melphalan—peripheral nervous system neoplasm	0.00172	0.00251	CcSEcCtD
Metoclopramide—Amenorrhoea—Doxorubicin—peripheral nervous system neoplasm	0.00171	0.00249	CcSEcCtD
Metoclopramide—Tachycardia—Isotretinoin—peripheral nervous system neoplasm	0.0017	0.00248	CcSEcCtD
Metoclopramide—Tachycardia—Tretinoin—peripheral nervous system neoplasm	0.0017	0.00248	CcSEcCtD
Metoclopramide—Neutropenia—Etoposide—peripheral nervous system neoplasm	0.0017	0.00248	CcSEcCtD
Metoclopramide—HTR3A—SIDS Susceptibility Pathways—TH—peripheral nervous system neoplasm	0.00169	0.00777	CbGpPWpGaD
Metoclopramide—Tachycardia—Melphalan—peripheral nervous system neoplasm	0.00168	0.00245	CcSEcCtD
Metoclopramide—Atrioventricular block—Epirubicin—peripheral nervous system neoplasm	0.00167	0.00244	CcSEcCtD
Metoclopramide—Hypotension—Tretinoin—peripheral nervous system neoplasm	0.00163	0.00238	CcSEcCtD
Metoclopramide—Hypotension—Isotretinoin—peripheral nervous system neoplasm	0.00163	0.00238	CcSEcCtD
Metoclopramide—Ventricular tachycardia—Epirubicin—peripheral nervous system neoplasm	0.00162	0.00237	CcSEcCtD
Metoclopramide—Bradycardia—Cisplatin—peripheral nervous system neoplasm	0.00161	0.00235	CcSEcCtD
Metoclopramide—Hypotension—Melphalan—peripheral nervous system neoplasm	0.00161	0.00235	CcSEcCtD
Metoclopramide—Dyskinesia—Doxorubicin—peripheral nervous system neoplasm	0.00159	0.00233	CcSEcCtD
Metoclopramide—DRD2—brainstem—peripheral nervous system neoplasm	0.00159	0.0273	CbGeAlD
Metoclopramide—Insomnia—Tretinoin—peripheral nervous system neoplasm	0.00158	0.0023	CcSEcCtD
Metoclopramide—Insomnia—Isotretinoin—peripheral nervous system neoplasm	0.00158	0.0023	CcSEcCtD
Metoclopramide—Jaundice—Etoposide—peripheral nervous system neoplasm	0.00158	0.0023	CcSEcCtD
Metoclopramide—Nervousness—Alitretinoin—peripheral nervous system neoplasm	0.00157	0.00229	CcSEcCtD
Metoclopramide—Dyspnoea—Topotecan—peripheral nervous system neoplasm	0.00157	0.00229	CcSEcCtD
Metoclopramide—Leukopenia—Dactinomycin—peripheral nervous system neoplasm	0.00156	0.00228	CcSEcCtD
Metoclopramide—Dyspnoea—Isotretinoin—peripheral nervous system neoplasm	0.00155	0.00227	CcSEcCtD
Metoclopramide—Dyspnoea—Tretinoin—peripheral nervous system neoplasm	0.00155	0.00227	CcSEcCtD
Metoclopramide—Somnolence—Tretinoin—peripheral nervous system neoplasm	0.00155	0.00226	CcSEcCtD
Metoclopramide—Somnolence—Isotretinoin—peripheral nervous system neoplasm	0.00155	0.00226	CcSEcCtD
Metoclopramide—Atrioventricular block—Doxorubicin—peripheral nervous system neoplasm	0.00155	0.00226	CcSEcCtD
Metoclopramide—Fluid retention—Epirubicin—peripheral nervous system neoplasm	0.00154	0.00225	CcSEcCtD
Metoclopramide—Dyspnoea—Melphalan—peripheral nervous system neoplasm	0.00153	0.00224	CcSEcCtD
Metoclopramide—Visual impairment—Cisplatin—peripheral nervous system neoplasm	0.00153	0.00223	CcSEcCtD
Metoclopramide—CYP11B1—Metabolism of lipids and lipoproteins—HSD17B12—peripheral nervous system neoplasm	0.00152	0.00698	CbGpPWpGaD
Metoclopramide—Tremor—Alitretinoin—peripheral nervous system neoplasm	0.00152	0.00221	CcSEcCtD
Metoclopramide—Fatigue—Topotecan—peripheral nervous system neoplasm	0.00151	0.00221	CcSEcCtD
Metoclopramide—Agranulocytosis—Etoposide—peripheral nervous system neoplasm	0.00151	0.0022	CcSEcCtD
Metoclopramide—Fatigue—Isotretinoin—peripheral nervous system neoplasm	0.0015	0.00219	CcSEcCtD
Metoclopramide—Fatigue—Tretinoin—peripheral nervous system neoplasm	0.0015	0.00219	CcSEcCtD
Metoclopramide—Ventricular tachycardia—Doxorubicin—peripheral nervous system neoplasm	0.0015	0.00219	CcSEcCtD
Metoclopramide—Agitation—Alitretinoin—peripheral nervous system neoplasm	0.00149	0.00217	CcSEcCtD
Metoclopramide—Fatigue—Melphalan—peripheral nervous system neoplasm	0.00148	0.00217	CcSEcCtD
Metoclopramide—Rash maculo-papular—Epirubicin—peripheral nervous system neoplasm	0.00147	0.00215	CcSEcCtD
Metoclopramide—Flushing—Cisplatin—peripheral nervous system neoplasm	0.00147	0.00215	CcSEcCtD
Metoclopramide—Feeling abnormal—Topotecan—peripheral nervous system neoplasm	0.00145	0.00211	CcSEcCtD
Metoclopramide—Feeling abnormal—Tretinoin—peripheral nervous system neoplasm	0.00144	0.0021	CcSEcCtD
Metoclopramide—Feeling abnormal—Isotretinoin—peripheral nervous system neoplasm	0.00144	0.0021	CcSEcCtD
Metoclopramide—Agitation—Vincristine—peripheral nervous system neoplasm	0.00143	0.00209	CcSEcCtD
Metoclopramide—Palpitations—Alitretinoin—peripheral nervous system neoplasm	0.00143	0.00209	CcSEcCtD
Metoclopramide—Oedema—Dactinomycin—peripheral nervous system neoplasm	0.00142	0.00208	CcSEcCtD
Metoclopramide—Fluid retention—Doxorubicin—peripheral nervous system neoplasm	0.00142	0.00208	CcSEcCtD
Metoclopramide—CYP17A1—Metabolism of lipids and lipoproteins—HSD17B12—peripheral nervous system neoplasm	0.00142	0.00653	CbGpPWpGaD
Metoclopramide—Convulsion—Alitretinoin—peripheral nervous system neoplasm	0.0014	0.00205	CcSEcCtD
Metoclopramide—Hypertension—Alitretinoin—peripheral nervous system neoplasm	0.0014	0.00204	CcSEcCtD
Metoclopramide—Leukopenia—Vincristine—peripheral nervous system neoplasm	0.0014	0.00204	CcSEcCtD
Metoclopramide—Urticaria—Topotecan—peripheral nervous system neoplasm	0.0014	0.00204	CcSEcCtD
Metoclopramide—Body temperature increased—Topotecan—peripheral nervous system neoplasm	0.00139	0.00203	CcSEcCtD
Metoclopramide—Urticaria—Tretinoin—peripheral nervous system neoplasm	0.00138	0.00202	CcSEcCtD
Metoclopramide—Urticaria—Isotretinoin—peripheral nervous system neoplasm	0.00138	0.00202	CcSEcCtD
Metoclopramide—Body temperature increased—Isotretinoin—peripheral nervous system neoplasm	0.00138	0.00201	CcSEcCtD
Metoclopramide—Body temperature increased—Tretinoin—peripheral nervous system neoplasm	0.00138	0.00201	CcSEcCtD
Metoclopramide—HTR3A—SIDS Susceptibility Pathways—BDNF—peripheral nervous system neoplasm	0.00138	0.00633	CbGpPWpGaD
Metoclopramide—Anxiety—Alitretinoin—peripheral nervous system neoplasm	0.00137	0.002	CcSEcCtD
Metoclopramide—Urticaria—Melphalan—peripheral nervous system neoplasm	0.00137	0.002	CcSEcCtD
Metoclopramide—Rash maculo-papular—Doxorubicin—peripheral nervous system neoplasm	0.00136	0.00199	CcSEcCtD
Metoclopramide—Convulsion—Vincristine—peripheral nervous system neoplasm	0.00135	0.00197	CcSEcCtD
Metoclopramide—Flushing—Etoposide—peripheral nervous system neoplasm	0.00135	0.00197	CcSEcCtD
Metoclopramide—Hypertension—Vincristine—peripheral nervous system neoplasm	0.00135	0.00197	CcSEcCtD
Metoclopramide—Confusional state—Alitretinoin—peripheral nervous system neoplasm	0.00133	0.00194	CcSEcCtD
Metoclopramide—Muscle spasms—Cisplatin—peripheral nervous system neoplasm	0.00133	0.00194	CcSEcCtD
Metoclopramide—Oedema—Alitretinoin—peripheral nervous system neoplasm	0.00132	0.00193	CcSEcCtD
Metoclopramide—Cardiac failure congestive—Epirubicin—peripheral nervous system neoplasm	0.0013	0.00189	CcSEcCtD
Metoclopramide—Hypersensitivity—Topotecan—peripheral nervous system neoplasm	0.00129	0.00189	CcSEcCtD
Metoclopramide—Tremor—Cisplatin—peripheral nervous system neoplasm	0.00129	0.00189	CcSEcCtD
Metoclopramide—Tachycardia—Alitretinoin—peripheral nervous system neoplasm	0.00129	0.00188	CcSEcCtD
Metoclopramide—Hypersensitivity—Tretinoin—peripheral nervous system neoplasm	0.00128	0.00187	CcSEcCtD
Metoclopramide—Hypersensitivity—Isotretinoin—peripheral nervous system neoplasm	0.00128	0.00187	CcSEcCtD
Metoclopramide—Oedema—Vincristine—peripheral nervous system neoplasm	0.00127	0.00186	CcSEcCtD
Metoclopramide—Hypersensitivity—Melphalan—peripheral nervous system neoplasm	0.00127	0.00185	CcSEcCtD
Metoclopramide—Asthenia—Topotecan—peripheral nervous system neoplasm	0.00126	0.00184	CcSEcCtD
Metoclopramide—Asthenia—Tretinoin—peripheral nervous system neoplasm	0.00125	0.00183	CcSEcCtD
Metoclopramide—Asthenia—Isotretinoin—peripheral nervous system neoplasm	0.00125	0.00183	CcSEcCtD
Metoclopramide—Renal impairment—Epirubicin—peripheral nervous system neoplasm	0.00124	0.0018	CcSEcCtD
Metoclopramide—HTR4—Class A/1 (Rhodopsin-like receptors)—KNG1—peripheral nervous system neoplasm	0.00123	0.00568	CbGpPWpGaD
Metoclopramide—Leukopenia—Cisplatin—peripheral nervous system neoplasm	0.00123	0.0018	CcSEcCtD
Metoclopramide—Asthenia—Melphalan—peripheral nervous system neoplasm	0.00123	0.0018	CcSEcCtD
Metoclopramide—Hypotension—Alitretinoin—peripheral nervous system neoplasm	0.00123	0.0018	CcSEcCtD
Metoclopramide—Fatigue—Dactinomycin—peripheral nervous system neoplasm	0.00123	0.00179	CcSEcCtD
Metoclopramide—Muscle spasms—Etoposide—peripheral nervous system neoplasm	0.00121	0.00177	CcSEcCtD
Metoclopramide—Diarrhoea—Topotecan—peripheral nervous system neoplasm	0.0012	0.00176	CcSEcCtD
Metoclopramide—Cardiac failure congestive—Doxorubicin—peripheral nervous system neoplasm	0.0012	0.00175	CcSEcCtD
Metoclopramide—Convulsion—Cisplatin—peripheral nervous system neoplasm	0.00119	0.00174	CcSEcCtD
Metoclopramide—Insomnia—Alitretinoin—peripheral nervous system neoplasm	0.00119	0.00174	CcSEcCtD
Metoclopramide—Diarrhoea—Tretinoin—peripheral nervous system neoplasm	0.00119	0.00174	CcSEcCtD
Metoclopramide—Diarrhoea—Isotretinoin—peripheral nervous system neoplasm	0.00119	0.00174	CcSEcCtD
Metoclopramide—Hypotension—Vincristine—peripheral nervous system neoplasm	0.00119	0.00174	CcSEcCtD
Metoclopramide—HTR4—GPCR downstream signaling—NTS—peripheral nervous system neoplasm	0.00118	0.00544	CbGpPWpGaD
Metoclopramide—Dyspnoea—Alitretinoin—peripheral nervous system neoplasm	0.00118	0.00172	CcSEcCtD
Metoclopramide—Diarrhoea—Melphalan—peripheral nervous system neoplasm	0.00118	0.00172	CcSEcCtD
Metoclopramide—Somnolence—Alitretinoin—peripheral nervous system neoplasm	0.00117	0.00171	CcSEcCtD
Metoclopramide—Feeling abnormal—Dactinomycin—peripheral nervous system neoplasm	0.00117	0.00171	CcSEcCtD
Metoclopramide—Anxiety—Cisplatin—peripheral nervous system neoplasm	0.00117	0.00171	CcSEcCtD
Metoclopramide—Dizziness—Topotecan—peripheral nervous system neoplasm	0.00116	0.0017	CcSEcCtD
Metoclopramide—CYP11B2—Metabolism—PPIP5K2—peripheral nervous system neoplasm	0.00116	0.00534	CbGpPWpGaD
Metoclopramide—Dizziness—Tretinoin—peripheral nervous system neoplasm	0.00115	0.00168	CcSEcCtD
Metoclopramide—Dizziness—Isotretinoin—peripheral nervous system neoplasm	0.00115	0.00168	CcSEcCtD
Metoclopramide—Insomnia—Vincristine—peripheral nervous system neoplasm	0.00115	0.00168	CcSEcCtD
Metoclopramide—Renal impairment—Doxorubicin—peripheral nervous system neoplasm	0.00114	0.00167	CcSEcCtD
Metoclopramide—Fatigue—Alitretinoin—peripheral nervous system neoplasm	0.00114	0.00166	CcSEcCtD
Metoclopramide—CHRM1—G alpha (q) signalling events—NTS—peripheral nervous system neoplasm	0.00113	0.00522	CbGpPWpGaD
Metoclopramide—Leukopenia—Etoposide—peripheral nervous system neoplasm	0.00113	0.00165	CcSEcCtD
Metoclopramide—Body temperature increased—Dactinomycin—peripheral nervous system neoplasm	0.00113	0.00164	CcSEcCtD
Metoclopramide—Oedema—Cisplatin—peripheral nervous system neoplasm	0.00113	0.00164	CcSEcCtD
Metoclopramide—Cardiac arrest—Epirubicin—peripheral nervous system neoplasm	0.00112	0.00163	CcSEcCtD
Metoclopramide—Rash—Topotecan—peripheral nervous system neoplasm	0.00111	0.00162	CcSEcCtD
Metoclopramide—Dermatitis—Topotecan—peripheral nervous system neoplasm	0.00111	0.00162	CcSEcCtD
Metoclopramide—Headache—Topotecan—peripheral nervous system neoplasm	0.0011	0.00161	CcSEcCtD
Metoclopramide—Rash—Tretinoin—peripheral nervous system neoplasm	0.0011	0.0016	CcSEcCtD
Metoclopramide—Rash—Isotretinoin—peripheral nervous system neoplasm	0.0011	0.0016	CcSEcCtD
Metoclopramide—Tachycardia—Cisplatin—peripheral nervous system neoplasm	0.0011	0.0016	CcSEcCtD
Metoclopramide—Dermatitis—Isotretinoin—peripheral nervous system neoplasm	0.0011	0.0016	CcSEcCtD
Metoclopramide—Dermatitis—Tretinoin—peripheral nervous system neoplasm	0.0011	0.0016	CcSEcCtD
Metoclopramide—Fatigue—Vincristine—peripheral nervous system neoplasm	0.0011	0.0016	CcSEcCtD
Metoclopramide—Convulsion—Etoposide—peripheral nervous system neoplasm	0.00109	0.0016	CcSEcCtD
Metoclopramide—HTR3A—Transmembrane transport of small molecules—COX2—peripheral nervous system neoplasm	0.00109	0.00503	CbGpPWpGaD
Metoclopramide—Headache—Isotretinoin—peripheral nervous system neoplasm	0.00109	0.00159	CcSEcCtD
Metoclopramide—Headache—Tretinoin—peripheral nervous system neoplasm	0.00109	0.00159	CcSEcCtD
Metoclopramide—Hypertension—Etoposide—peripheral nervous system neoplasm	0.00109	0.00159	CcSEcCtD
Metoclopramide—Feeling abnormal—Alitretinoin—peripheral nervous system neoplasm	0.00109	0.00159	CcSEcCtD
Metoclopramide—Rash—Melphalan—peripheral nervous system neoplasm	0.00108	0.00158	CcSEcCtD
Metoclopramide—Dermatitis—Melphalan—peripheral nervous system neoplasm	0.00108	0.00158	CcSEcCtD
Metoclopramide—HTR4—Signaling by GPCR—NTS—peripheral nervous system neoplasm	0.00107	0.00494	CbGpPWpGaD
Metoclopramide—Hypotension—Cisplatin—peripheral nervous system neoplasm	0.00105	0.00154	CcSEcCtD
Metoclopramide—Hypersensitivity—Dactinomycin—peripheral nervous system neoplasm	0.00105	0.00153	CcSEcCtD
Metoclopramide—Urticaria—Alitretinoin—peripheral nervous system neoplasm	0.00105	0.00153	CcSEcCtD
Metoclopramide—Body temperature increased—Alitretinoin—peripheral nervous system neoplasm	0.00104	0.00152	CcSEcCtD
Metoclopramide—Nausea—Topotecan—peripheral nervous system neoplasm	0.00104	0.00152	CcSEcCtD
Metoclopramide—Confusional state—Etoposide—peripheral nervous system neoplasm	0.00104	0.00152	CcSEcCtD
Metoclopramide—Nausea—Tretinoin—peripheral nervous system neoplasm	0.00104	0.00151	CcSEcCtD
Metoclopramide—Nausea—Isotretinoin—peripheral nervous system neoplasm	0.00104	0.00151	CcSEcCtD
Metoclopramide—Cardiac arrest—Doxorubicin—peripheral nervous system neoplasm	0.00103	0.00151	CcSEcCtD
Metoclopramide—HTR4—Signaling by GPCR—CD55—peripheral nervous system neoplasm	0.00103	0.00474	CbGpPWpGaD
Metoclopramide—Asthenia—Dactinomycin—peripheral nervous system neoplasm	0.00102	0.00149	CcSEcCtD
Metoclopramide—Nausea—Melphalan—peripheral nervous system neoplasm	0.00102	0.00149	CcSEcCtD
Metoclopramide—Asthma—Epirubicin—peripheral nervous system neoplasm	0.00102	0.00148	CcSEcCtD
Metoclopramide—CHRM1—Gastrin-CREB signalling pathway via PKC and MAPK—NTS—peripheral nervous system neoplasm	0.00101	0.00467	CbGpPWpGaD
Metoclopramide—Tachycardia—Etoposide—peripheral nervous system neoplasm	0.00101	0.00147	CcSEcCtD
Metoclopramide—Body temperature increased—Vincristine—peripheral nervous system neoplasm	0.00101	0.00147	CcSEcCtD
Metoclopramide—Dyspnoea—Cisplatin—peripheral nervous system neoplasm	0.001	0.00146	CcSEcCtD
Metoclopramide—DRD3—Class A/1 (Rhodopsin-like receptors)—NTS—peripheral nervous system neoplasm	0.001	0.00462	CbGpPWpGaD
Metoclopramide—CYP11B1—Metabolism—PPIP5K2—peripheral nervous system neoplasm	0.001	0.0046	CbGpPWpGaD
Metoclopramide—Diarrhoea—Dactinomycin—peripheral nervous system neoplasm	0.000975	0.00142	CcSEcCtD
Metoclopramide—Hypersensitivity—Alitretinoin—peripheral nervous system neoplasm	0.000973	0.00142	CcSEcCtD
Metoclopramide—Hypotension—Etoposide—peripheral nervous system neoplasm	0.000963	0.00141	CcSEcCtD
Metoclopramide—CYP2D6—brainstem—peripheral nervous system neoplasm	0.000956	0.0164	CbGeAlD
Metoclopramide—Neutropenia—Epirubicin—peripheral nervous system neoplasm	0.00095	0.00139	CcSEcCtD
Metoclopramide—Asthenia—Alitretinoin—peripheral nervous system neoplasm	0.000948	0.00138	CcSEcCtD
Metoclopramide—Asthma—Doxorubicin—peripheral nervous system neoplasm	0.00094	0.00137	CcSEcCtD
Metoclopramide—HTR4—GPCR ligand binding—KNG1—peripheral nervous system neoplasm	0.00094	0.00432	CbGpPWpGaD
Metoclopramide—Pollakiuria—Epirubicin—peripheral nervous system neoplasm	0.000939	0.00137	CcSEcCtD
Metoclopramide—Hypersensitivity—Vincristine—peripheral nervous system neoplasm	0.000938	0.00137	CcSEcCtD
Metoclopramide—CYP17A1—Metabolism—PPIP5K2—peripheral nervous system neoplasm	0.000936	0.00431	CbGpPWpGaD
Metoclopramide—Feeling abnormal—Cisplatin—peripheral nervous system neoplasm	0.000927	0.00135	CcSEcCtD
Metoclopramide—CYP11B1—Corticotropin-releasing hormone—CASP3—peripheral nervous system neoplasm	0.000924	0.00425	CbGpPWpGaD
Metoclopramide—Dyspnoea—Etoposide—peripheral nervous system neoplasm	0.000919	0.00134	CcSEcCtD
Metoclopramide—Somnolence—Etoposide—peripheral nervous system neoplasm	0.000917	0.00134	CcSEcCtD
Metoclopramide—Asthenia—Vincristine—peripheral nervous system neoplasm	0.000913	0.00133	CcSEcCtD
Metoclopramide—Drowsiness—Epirubicin—peripheral nervous system neoplasm	0.000906	0.00132	CcSEcCtD
Metoclopramide—Diarrhoea—Alitretinoin—peripheral nervous system neoplasm	0.000904	0.00132	CcSEcCtD
Metoclopramide—Rash—Dactinomycin—peripheral nervous system neoplasm	0.000898	0.00131	CcSEcCtD
Metoclopramide—HTR4—GPCR downstream signaling—VIP—peripheral nervous system neoplasm	0.000896	0.00412	CbGpPWpGaD
Metoclopramide—Body temperature increased—Cisplatin—peripheral nervous system neoplasm	0.00089	0.0013	CcSEcCtD
Metoclopramide—Fatigue—Etoposide—peripheral nervous system neoplasm	0.000889	0.0013	CcSEcCtD
Metoclopramide—Jaundice—Epirubicin—peripheral nervous system neoplasm	0.000883	0.00129	CcSEcCtD
Metoclopramide—Neutropenia—Doxorubicin—peripheral nervous system neoplasm	0.000879	0.00128	CcSEcCtD
Metoclopramide—Dizziness—Alitretinoin—peripheral nervous system neoplasm	0.000873	0.00128	CcSEcCtD
Metoclopramide—Diarrhoea—Vincristine—peripheral nervous system neoplasm	0.000871	0.00127	CcSEcCtD
Metoclopramide—Pollakiuria—Doxorubicin—peripheral nervous system neoplasm	0.000869	0.00127	CcSEcCtD
Metoclopramide—Sunitinib—ABCB1—peripheral nervous system neoplasm	0.000853	0.0216	CrCbGaD
Metoclopramide—Feeling abnormal—Etoposide—peripheral nervous system neoplasm	0.00085	0.00124	CcSEcCtD
Metoclopramide—Nausea—Dactinomycin—peripheral nervous system neoplasm	0.000846	0.00124	CcSEcCtD
Metoclopramide—Agranulocytosis—Epirubicin—peripheral nervous system neoplasm	0.000846	0.00123	CcSEcCtD
Metoclopramide—Dizziness—Vincristine—peripheral nervous system neoplasm	0.000842	0.00123	CcSEcCtD
Metoclopramide—Drowsiness—Doxorubicin—peripheral nervous system neoplasm	0.000838	0.00122	CcSEcCtD
Metoclopramide—Rash—Alitretinoin—peripheral nervous system neoplasm	0.000833	0.00122	CcSEcCtD
Metoclopramide—Dermatitis—Alitretinoin—peripheral nervous system neoplasm	0.000832	0.00121	CcSEcCtD
Metoclopramide—Hypersensitivity—Cisplatin—peripheral nervous system neoplasm	0.000829	0.00121	CcSEcCtD
Metoclopramide—Bradycardia—Epirubicin—peripheral nervous system neoplasm	0.000828	0.00121	CcSEcCtD
Metoclopramide—Headache—Alitretinoin—peripheral nervous system neoplasm	0.000827	0.00121	CcSEcCtD
Metoclopramide—HTR4—GPCR ligand binding—GNAS—peripheral nervous system neoplasm	0.000822	0.00378	CbGpPWpGaD
Metoclopramide—Urticaria—Etoposide—peripheral nervous system neoplasm	0.000819	0.0012	CcSEcCtD
Metoclopramide—Jaundice—Doxorubicin—peripheral nervous system neoplasm	0.000817	0.00119	CcSEcCtD
Metoclopramide—Body temperature increased—Etoposide—peripheral nervous system neoplasm	0.000815	0.00119	CcSEcCtD
Metoclopramide—HTR4—Signaling by GPCR—VIP—peripheral nervous system neoplasm	0.000814	0.00374	CbGpPWpGaD
Metoclopramide—Asthenia—Cisplatin—peripheral nervous system neoplasm	0.000807	0.00118	CcSEcCtD
Metoclopramide—Rash—Vincristine—peripheral nervous system neoplasm	0.000803	0.00117	CcSEcCtD
Metoclopramide—Dermatitis—Vincristine—peripheral nervous system neoplasm	0.000802	0.00117	CcSEcCtD
Metoclopramide—Headache—Vincristine—peripheral nervous system neoplasm	0.000797	0.00116	CcSEcCtD
Metoclopramide—DRD2—cerebellum—peripheral nervous system neoplasm	0.000785	0.0135	CbGeAlD
Metoclopramide—Nausea—Alitretinoin—peripheral nervous system neoplasm	0.000785	0.00115	CcSEcCtD
Metoclopramide—CYP11B2—Metabolism—HSD17B12—peripheral nervous system neoplasm	0.000784	0.00361	CbGpPWpGaD
Metoclopramide—Visual impairment—Epirubicin—peripheral nervous system neoplasm	0.000784	0.00114	CcSEcCtD
Metoclopramide—Agranulocytosis—Doxorubicin—peripheral nervous system neoplasm	0.000782	0.00114	CcSEcCtD
Metoclopramide—Diarrhoea—Cisplatin—peripheral nervous system neoplasm	0.00077	0.00112	CcSEcCtD
Metoclopramide—DRD2—Class A/1 (Rhodopsin-like receptors)—NTS—peripheral nervous system neoplasm	0.000768	0.00353	CbGpPWpGaD
Metoclopramide—Bradycardia—Doxorubicin—peripheral nervous system neoplasm	0.000766	0.00112	CcSEcCtD
Metoclopramide—DRD3—GPCR ligand binding—NTS—peripheral nervous system neoplasm	0.000764	0.00351	CbGpPWpGaD
Metoclopramide—Hypersensitivity—Etoposide—peripheral nervous system neoplasm	0.00076	0.00111	CcSEcCtD
Metoclopramide—Nausea—Vincristine—peripheral nervous system neoplasm	0.000756	0.0011	CcSEcCtD
Metoclopramide—Flushing—Epirubicin—peripheral nervous system neoplasm	0.000755	0.0011	CcSEcCtD
Metoclopramide—CHRM1—Class A/1 (Rhodopsin-like receptors)—NTS—peripheral nervous system neoplasm	0.000751	0.00346	CbGpPWpGaD
Metoclopramide—HTR4—Signaling by GPCR—PPP3R1—peripheral nervous system neoplasm	0.000751	0.00345	CbGpPWpGaD
Metoclopramide—Asthenia—Etoposide—peripheral nervous system neoplasm	0.00074	0.00108	CcSEcCtD
Metoclopramide—DRD3—GPCR ligand binding—CD55—peripheral nervous system neoplasm	0.000732	0.00337	CbGpPWpGaD
Metoclopramide—Visual impairment—Doxorubicin—peripheral nervous system neoplasm	0.000725	0.00106	CcSEcCtD
Metoclopramide—Rash—Cisplatin—peripheral nervous system neoplasm	0.00071	0.00104	CcSEcCtD
Metoclopramide—Dermatitis—Cisplatin—peripheral nervous system neoplasm	0.000709	0.00104	CcSEcCtD
Metoclopramide—Diarrhoea—Etoposide—peripheral nervous system neoplasm	0.000705	0.00103	CcSEcCtD
Metoclopramide—Flushing—Doxorubicin—peripheral nervous system neoplasm	0.000699	0.00102	CcSEcCtD
Metoclopramide—DRD3—Circadian rythm related genes—TH—peripheral nervous system neoplasm	0.000688	0.00317	CbGpPWpGaD
Metoclopramide—Nervousness—Epirubicin—peripheral nervous system neoplasm	0.000688	0.001	CcSEcCtD
Metoclopramide—HTR3A—SIDS Susceptibility Pathways—CASP3—peripheral nervous system neoplasm	0.000688	0.00316	CbGpPWpGaD
Metoclopramide—Dizziness—Etoposide—peripheral nervous system neoplasm	0.000682	0.000995	CcSEcCtD
Metoclopramide—Muscle spasms—Epirubicin—peripheral nervous system neoplasm	0.000681	0.000994	CcSEcCtD
Metoclopramide—CYP11B1—Metabolism—HSD17B12—peripheral nervous system neoplasm	0.000676	0.00311	CbGpPWpGaD
Metoclopramide—Nausea—Cisplatin—peripheral nervous system neoplasm	0.000668	0.000976	CcSEcCtD
Metoclopramide—CYP11B2—Metabolism of lipids and lipoproteins—BCHE—peripheral nervous system neoplasm	0.000652	0.003	CbGpPWpGaD
Metoclopramide—Agitation—Epirubicin—peripheral nervous system neoplasm	0.000651	0.00095	CcSEcCtD
Metoclopramide—Rash—Etoposide—peripheral nervous system neoplasm	0.00065	0.000949	CcSEcCtD
Metoclopramide—Dermatitis—Etoposide—peripheral nervous system neoplasm	0.000649	0.000948	CcSEcCtD
Metoclopramide—Headache—Etoposide—peripheral nervous system neoplasm	0.000646	0.000943	CcSEcCtD
Metoclopramide—Nervousness—Doxorubicin—peripheral nervous system neoplasm	0.000636	0.000929	CcSEcCtD
Metoclopramide—HTR4—Signaling Pathways—NTS—peripheral nervous system neoplasm	0.000634	0.00292	CbGpPWpGaD
Metoclopramide—Leukopenia—Epirubicin—peripheral nervous system neoplasm	0.000634	0.000925	CcSEcCtD
Metoclopramide—CYP17A1—Metabolism—HSD17B12—peripheral nervous system neoplasm	0.000632	0.00291	CbGpPWpGaD
Metoclopramide—Muscle spasms—Doxorubicin—peripheral nervous system neoplasm	0.00063	0.00092	CcSEcCtD
Metoclopramide—Palpitations—Epirubicin—peripheral nervous system neoplasm	0.000626	0.000914	CcSEcCtD
Metoclopramide—Convulsion—Epirubicin—peripheral nervous system neoplasm	0.000614	0.000896	CcSEcCtD
Metoclopramide—Nausea—Etoposide—peripheral nervous system neoplasm	0.000612	0.000894	CcSEcCtD
Metoclopramide—DRD3—Circadian rythm related genes—NTRK1—peripheral nervous system neoplasm	0.000612	0.00282	CbGpPWpGaD
Metoclopramide—Hypertension—Epirubicin—peripheral nervous system neoplasm	0.000611	0.000893	CcSEcCtD
Metoclopramide—HTR4—Signaling Pathways—CD55—peripheral nervous system neoplasm	0.000608	0.0028	CbGpPWpGaD
Metoclopramide—Agitation—Doxorubicin—peripheral nervous system neoplasm	0.000602	0.000879	CcSEcCtD
Metoclopramide—Anxiety—Epirubicin—peripheral nervous system neoplasm	0.000601	0.000877	CcSEcCtD
Metoclopramide—Leukopenia—Doxorubicin—peripheral nervous system neoplasm	0.000587	0.000856	CcSEcCtD
Metoclopramide—DRD2—GPCR ligand binding—NTS—peripheral nervous system neoplasm	0.000585	0.00269	CbGpPWpGaD
Metoclopramide—Confusional state—Epirubicin—peripheral nervous system neoplasm	0.000583	0.000851	CcSEcCtD
Metoclopramide—Palpitations—Doxorubicin—peripheral nervous system neoplasm	0.000579	0.000845	CcSEcCtD
Metoclopramide—HTR3A—Transmembrane transport of small molecules—SLC2A1—peripheral nervous system neoplasm	0.000579	0.00266	CbGpPWpGaD
Metoclopramide—Oedema—Epirubicin—peripheral nervous system neoplasm	0.000578	0.000844	CcSEcCtD
Metoclopramide—CHRM1—GPCR ligand binding—NTS—peripheral nervous system neoplasm	0.000572	0.00263	CbGpPWpGaD
Metoclopramide—Convulsion—Doxorubicin—peripheral nervous system neoplasm	0.000568	0.000829	CcSEcCtD
Metoclopramide—CYP11B2—Metabolism—GNS—peripheral nervous system neoplasm	0.000567	0.00261	CbGpPWpGaD
Metoclopramide—DRD3—G alpha (i) signalling events—KNG1—peripheral nervous system neoplasm	0.000567	0.00261	CbGpPWpGaD
Metoclopramide—Hypertension—Doxorubicin—peripheral nervous system neoplasm	0.000566	0.000826	CcSEcCtD
Metoclopramide—Tachycardia—Epirubicin—peripheral nervous system neoplasm	0.000564	0.000824	CcSEcCtD
Metoclopramide—CYP11B1—Metabolism of lipids and lipoproteins—BCHE—peripheral nervous system neoplasm	0.000562	0.00258	CbGpPWpGaD
Metoclopramide—DRD2—GPCR ligand binding—CD55—peripheral nervous system neoplasm	0.00056	0.00258	CbGpPWpGaD
Metoclopramide—Anxiety—Doxorubicin—peripheral nervous system neoplasm	0.000556	0.000812	CcSEcCtD
Metoclopramide—CHRM1—GPCR ligand binding—CD55—peripheral nervous system neoplasm	0.000549	0.00252	CbGpPWpGaD
Metoclopramide—CYP11B2—Metabolism—NME1—peripheral nervous system neoplasm	0.000544	0.0025	CbGpPWpGaD
Metoclopramide—Hypotension—Epirubicin—peripheral nervous system neoplasm	0.00054	0.000788	CcSEcCtD
Metoclopramide—Confusional state—Doxorubicin—peripheral nervous system neoplasm	0.000539	0.000787	CcSEcCtD
Metoclopramide—Oedema—Doxorubicin—peripheral nervous system neoplasm	0.000535	0.000781	CcSEcCtD
Metoclopramide—CHRM1—Calcium Regulation in the Cardiac Cell—GNAS—peripheral nervous system neoplasm	0.000535	0.00246	CbGpPWpGaD
Metoclopramide—HTR4—GPCR downstream signaling—KNG1—peripheral nervous system neoplasm	0.000531	0.00244	CbGpPWpGaD
Metoclopramide—DRD2—Circadian rythm related genes—TH—peripheral nervous system neoplasm	0.000527	0.00242	CbGpPWpGaD
Metoclopramide—CYP17A1—Metabolism of lipids and lipoproteins—BCHE—peripheral nervous system neoplasm	0.000526	0.00242	CbGpPWpGaD
Metoclopramide—CYP11B2—Metabolism—COX2—peripheral nervous system neoplasm	0.000523	0.00241	CbGpPWpGaD
Metoclopramide—Insomnia—Epirubicin—peripheral nervous system neoplasm	0.000523	0.000763	CcSEcCtD
Metoclopramide—Tachycardia—Doxorubicin—peripheral nervous system neoplasm	0.000522	0.000762	CcSEcCtD
Metoclopramide—CHRM1—Circadian rythm related genes—TH—peripheral nervous system neoplasm	0.000515	0.00237	CbGpPWpGaD
Metoclopramide—Dyspnoea—Epirubicin—peripheral nervous system neoplasm	0.000515	0.000752	CcSEcCtD
Metoclopramide—Somnolence—Epirubicin—peripheral nervous system neoplasm	0.000514	0.00075	CcSEcCtD
Metoclopramide—CHRM1—G alpha (q) signalling events—KNG1—peripheral nervous system neoplasm	0.00051	0.00235	CbGpPWpGaD
Metoclopramide—CYP11B1—Corticotropin-releasing hormone—AKT1—peripheral nervous system neoplasm	0.0005	0.0023	CbGpPWpGaD
Metoclopramide—Hypotension—Doxorubicin—peripheral nervous system neoplasm	0.0005	0.00073	CcSEcCtD
Metoclopramide—Fatigue—Epirubicin—peripheral nervous system neoplasm	0.000498	0.000727	CcSEcCtD
Metoclopramide—DRD3—G alpha (i) signalling events—GNAS—peripheral nervous system neoplasm	0.000496	0.00228	CbGpPWpGaD
Metoclopramide—CYP11B1—Metabolism—GNS—peripheral nervous system neoplasm	0.000489	0.00225	CbGpPWpGaD
Metoclopramide—Insomnia—Doxorubicin—peripheral nervous system neoplasm	0.000484	0.000706	CcSEcCtD
Metoclopramide—HTR4—Signaling by GPCR—KNG1—peripheral nervous system neoplasm	0.000482	0.00222	CbGpPWpGaD
Metoclopramide—HTR4—Signaling Pathways—VIP—peripheral nervous system neoplasm	0.000481	0.00221	CbGpPWpGaD
Metoclopramide—Dyspnoea—Doxorubicin—peripheral nervous system neoplasm	0.000477	0.000696	CcSEcCtD
Metoclopramide—Feeling abnormal—Epirubicin—peripheral nervous system neoplasm	0.000476	0.000695	CcSEcCtD
Metoclopramide—Somnolence—Doxorubicin—peripheral nervous system neoplasm	0.000475	0.000694	CcSEcCtD
Metoclopramide—CYP2D6—cerebellum—peripheral nervous system neoplasm	0.000471	0.0081	CbGeAlD
Metoclopramide—CYP11B1—Metabolism—NME1—peripheral nervous system neoplasm	0.000469	0.00216	CbGpPWpGaD
Metoclopramide—DRD2—Circadian rythm related genes—NTRK1—peripheral nervous system neoplasm	0.000469	0.00216	CbGpPWpGaD
Metoclopramide—HTR3A—Transmembrane transport of small molecules—GNAS—peripheral nervous system neoplasm	0.000466	0.00214	CbGpPWpGaD
Metoclopramide—HTR4—GPCR downstream signaling—GNAS—peripheral nervous system neoplasm	0.000465	0.00214	CbGpPWpGaD
Metoclopramide—Fatigue—Doxorubicin—peripheral nervous system neoplasm	0.000461	0.000673	CcSEcCtD
Metoclopramide—Urticaria—Epirubicin—peripheral nervous system neoplasm	0.000459	0.00067	CcSEcCtD
Metoclopramide—CHRM1—Circadian rythm related genes—NTRK1—peripheral nervous system neoplasm	0.000459	0.00211	CbGpPWpGaD
Metoclopramide—CYP17A1—Metabolism—GNS—peripheral nervous system neoplasm	0.000457	0.0021	CbGpPWpGaD
Metoclopramide—HTR3A—Transmembrane transport of small molecules—ABCB1—peripheral nervous system neoplasm	0.000457	0.0021	CbGpPWpGaD
Metoclopramide—Body temperature increased—Epirubicin—peripheral nervous system neoplasm	0.000457	0.000667	CcSEcCtD
Metoclopramide—CHRM1—Gastrin-CREB signalling pathway via PKC and MAPK—KNG1—peripheral nervous system neoplasm	0.000456	0.0021	CbGpPWpGaD
Metoclopramide—CYP11B1—Metabolism—COX2—peripheral nervous system neoplasm	0.000451	0.00208	CbGpPWpGaD
Metoclopramide—DRD3—Class A/1 (Rhodopsin-like receptors)—KNG1—peripheral nervous system neoplasm	0.000451	0.00207	CbGpPWpGaD
Metoclopramide—HTR4—Signaling Pathways—PPP3R1—peripheral nervous system neoplasm	0.000444	0.00204	CbGpPWpGaD
Metoclopramide—Feeling abnormal—Doxorubicin—peripheral nervous system neoplasm	0.000441	0.000643	CcSEcCtD
Metoclopramide—CYP17A1—Metabolism—NME1—peripheral nervous system neoplasm	0.000438	0.00202	CbGpPWpGaD
Metoclopramide—DRD2—G alpha (i) signalling events—KNG1—peripheral nervous system neoplasm	0.000434	0.002	CbGpPWpGaD
Metoclopramide—DRD3—GPCR downstream signaling—NTS—peripheral nervous system neoplasm	0.000432	0.00199	CbGpPWpGaD
Metoclopramide—Hypersensitivity—Epirubicin—peripheral nervous system neoplasm	0.000426	0.000622	CcSEcCtD
Metoclopramide—Urticaria—Doxorubicin—peripheral nervous system neoplasm	0.000425	0.00062	CcSEcCtD
Metoclopramide—Body temperature increased—Doxorubicin—peripheral nervous system neoplasm	0.000423	0.000617	CcSEcCtD
Metoclopramide—CYP17A1—Metabolism—COX2—peripheral nervous system neoplasm	0.000422	0.00194	CbGpPWpGaD
Metoclopramide—HTR4—Signaling by GPCR—GNAS—peripheral nervous system neoplasm	0.000422	0.00194	CbGpPWpGaD
Metoclopramide—Asthenia—Epirubicin—peripheral nervous system neoplasm	0.000415	0.000605	CcSEcCtD
Metoclopramide—Diarrhoea—Epirubicin—peripheral nervous system neoplasm	0.000395	0.000577	CcSEcCtD
Metoclopramide—Hypersensitivity—Doxorubicin—peripheral nervous system neoplasm	0.000394	0.000575	CcSEcCtD
Metoclopramide—DRD3—Signaling by GPCR—NTS—peripheral nervous system neoplasm	0.000392	0.0018	CbGpPWpGaD
Metoclopramide—Asthenia—Doxorubicin—peripheral nervous system neoplasm	0.000384	0.00056	CcSEcCtD
Metoclopramide—Dizziness—Epirubicin—peripheral nervous system neoplasm	0.000382	0.000558	CcSEcCtD
Metoclopramide—DRD2—G alpha (i) signalling events—GNAS—peripheral nervous system neoplasm	0.000379	0.00175	CbGpPWpGaD
Metoclopramide—DRD3—Signaling by GPCR—CD55—peripheral nervous system neoplasm	0.000376	0.00173	CbGpPWpGaD
Metoclopramide—Diarrhoea—Doxorubicin—peripheral nervous system neoplasm	0.000366	0.000534	CcSEcCtD
Metoclopramide—Rash—Epirubicin—peripheral nervous system neoplasm	0.000364	0.000532	CcSEcCtD
Metoclopramide—Dermatitis—Epirubicin—peripheral nervous system neoplasm	0.000364	0.000532	CcSEcCtD
Metoclopramide—Headache—Epirubicin—peripheral nervous system neoplasm	0.000362	0.000529	CcSEcCtD
Metoclopramide—Dizziness—Doxorubicin—peripheral nervous system neoplasm	0.000354	0.000516	CcSEcCtD
Metoclopramide—DRD2—Class A/1 (Rhodopsin-like receptors)—KNG1—peripheral nervous system neoplasm	0.000345	0.00159	CbGpPWpGaD
Metoclopramide—CYP11B2—Metabolism—ENO2—peripheral nervous system neoplasm	0.000344	0.00158	CbGpPWpGaD
Metoclopramide—Nausea—Epirubicin—peripheral nervous system neoplasm	0.000343	0.000501	CcSEcCtD
Metoclopramide—DRD3—GPCR ligand binding—KNG1—peripheral nervous system neoplasm	0.000343	0.00158	CbGpPWpGaD
Metoclopramide—CHRM1—Class A/1 (Rhodopsin-like receptors)—KNG1—peripheral nervous system neoplasm	0.000338	0.00155	CbGpPWpGaD
Metoclopramide—Rash—Doxorubicin—peripheral nervous system neoplasm	0.000337	0.000492	CcSEcCtD
Metoclopramide—Dermatitis—Doxorubicin—peripheral nervous system neoplasm	0.000337	0.000492	CcSEcCtD
Metoclopramide—Headache—Doxorubicin—peripheral nervous system neoplasm	0.000335	0.000489	CcSEcCtD
Metoclopramide—HTR4—Signaling Pathways—NTRK2—peripheral nervous system neoplasm	0.000333	0.00153	CbGpPWpGaD
Metoclopramide—DRD2—GPCR downstream signaling—NTS—peripheral nervous system neoplasm	0.00033	0.00152	CbGpPWpGaD
Metoclopramide—DRD3—GPCR downstream signaling—VIP—peripheral nervous system neoplasm	0.000327	0.00151	CbGpPWpGaD
Metoclopramide—CHRM1—GPCR downstream signaling—NTS—peripheral nervous system neoplasm	0.000323	0.00149	CbGpPWpGaD
Metoclopramide—Nausea—Doxorubicin—peripheral nervous system neoplasm	0.000318	0.000464	CcSEcCtD
Metoclopramide—DRD3—GPCR ligand binding—GNAS—peripheral nervous system neoplasm	0.0003	0.00138	CbGpPWpGaD
Metoclopramide—DRD2—Signaling by GPCR—NTS—peripheral nervous system neoplasm	0.0003	0.00138	CbGpPWpGaD
Metoclopramide—DRD3—Signaling by GPCR—VIP—peripheral nervous system neoplasm	0.000297	0.00137	CbGpPWpGaD
Metoclopramide—CYP11B1—Metabolism—ENO2—peripheral nervous system neoplasm	0.000296	0.00136	CbGpPWpGaD
Metoclopramide—CHRM1—Signaling by GPCR—NTS—peripheral nervous system neoplasm	0.000294	0.00135	CbGpPWpGaD
Metoclopramide—HTR4—Signaling by GPCR—PTPN11—peripheral nervous system neoplasm	0.000293	0.00135	CbGpPWpGaD
Metoclopramide—CYP11B2—Metabolism—BCHE—peripheral nervous system neoplasm	0.00029	0.00134	CbGpPWpGaD
Metoclopramide—DRD2—Signaling by GPCR—CD55—peripheral nervous system neoplasm	0.000288	0.00132	CbGpPWpGaD
Metoclopramide—HTR4—Signaling Pathways—KNG1—peripheral nervous system neoplasm	0.000285	0.00131	CbGpPWpGaD
Metoclopramide—CHRM1—Signaling by GPCR—CD55—peripheral nervous system neoplasm	0.000281	0.0013	CbGpPWpGaD
Metoclopramide—CHRM1—Gastrin-CREB signalling pathway via PKC and MAPK—PTPN11—peripheral nervous system neoplasm	0.000277	0.00127	CbGpPWpGaD
Metoclopramide—CYP11B2—Metabolism—SLC2A1—peripheral nervous system neoplasm	0.000277	0.00127	CbGpPWpGaD
Metoclopramide—CYP17A1—Metabolism—ENO2—peripheral nervous system neoplasm	0.000277	0.00127	CbGpPWpGaD
Metoclopramide—DRD3—Signaling by GPCR—PPP3R1—peripheral nervous system neoplasm	0.000274	0.00126	CbGpPWpGaD
Metoclopramide—CYP11B2—Metabolism—TH—peripheral nervous system neoplasm	0.000273	0.00126	CbGpPWpGaD
Metoclopramide—HTR4—Signaling Pathways—NTRK1—peripheral nervous system neoplasm	0.000272	0.00125	CbGpPWpGaD
Metoclopramide—DRD2—GPCR ligand binding—KNG1—peripheral nervous system neoplasm	0.000263	0.00121	CbGpPWpGaD
Metoclopramide—CHRM1—GPCR ligand binding—KNG1—peripheral nervous system neoplasm	0.000257	0.00118	CbGpPWpGaD
Metoclopramide—CYP2D6—Metabolism—PPIP5K2—peripheral nervous system neoplasm	0.000253	0.00116	CbGpPWpGaD
Metoclopramide—DRD2—GPCR downstream signaling—VIP—peripheral nervous system neoplasm	0.00025	0.00115	CbGpPWpGaD
Metoclopramide—CYP11B1—Metabolism—BCHE—peripheral nervous system neoplasm	0.00025	0.00115	CbGpPWpGaD
Metoclopramide—HTR4—Signaling Pathways—GNAS—peripheral nervous system neoplasm	0.000249	0.00115	CbGpPWpGaD
Metoclopramide—CHRM1—GPCR downstream signaling—VIP—peripheral nervous system neoplasm	0.000245	0.00113	CbGpPWpGaD
Metoclopramide—CYP11B1—Metabolism—SLC2A1—peripheral nervous system neoplasm	0.000239	0.0011	CbGpPWpGaD
Metoclopramide—CYP11B1—Metabolism—TH—peripheral nervous system neoplasm	0.000235	0.00108	CbGpPWpGaD
Metoclopramide—CYP17A1—Metabolism—BCHE—peripheral nervous system neoplasm	0.000234	0.00108	CbGpPWpGaD
Metoclopramide—DRD3—Signaling Pathways—NTS—peripheral nervous system neoplasm	0.000232	0.00107	CbGpPWpGaD
Metoclopramide—DRD2—GPCR ligand binding—GNAS—peripheral nervous system neoplasm	0.00023	0.00106	CbGpPWpGaD
Metoclopramide—DRD2—Signaling by GPCR—VIP—peripheral nervous system neoplasm	0.000227	0.00105	CbGpPWpGaD
Metoclopramide—CHRM1—GPCR ligand binding—GNAS—peripheral nervous system neoplasm	0.000225	0.00103	CbGpPWpGaD
Metoclopramide—CHRM1—Regulation of Actin Cytoskeleton—NRAS—peripheral nervous system neoplasm	0.000223	0.00103	CbGpPWpGaD
Metoclopramide—CYP17A1—Metabolism—SLC2A1—peripheral nervous system neoplasm	0.000223	0.00103	CbGpPWpGaD
Metoclopramide—CYP11B2—Metabolism—GNAS—peripheral nervous system neoplasm	0.000223	0.00103	CbGpPWpGaD
Metoclopramide—CHRM1—Signaling by GPCR—VIP—peripheral nervous system neoplasm	0.000223	0.00102	CbGpPWpGaD
Metoclopramide—DRD3—Signaling Pathways—CD55—peripheral nervous system neoplasm	0.000222	0.00102	CbGpPWpGaD
Metoclopramide—CYP17A1—Metabolism—TH—peripheral nervous system neoplasm	0.00022	0.00101	CbGpPWpGaD
Metoclopramide—CYP11B2—Metabolism—ABCB1—peripheral nervous system neoplasm	0.000219	0.00101	CbGpPWpGaD
Metoclopramide—DRD2—Signaling by GPCR—PPP3R1—peripheral nervous system neoplasm	0.00021	0.000965	CbGpPWpGaD
Metoclopramide—CHRM1—Signaling by GPCR—PPP3R1—peripheral nervous system neoplasm	0.000205	0.000945	CbGpPWpGaD
Metoclopramide—DRD3—GPCR downstream signaling—KNG1—peripheral nervous system neoplasm	0.000194	0.000892	CbGpPWpGaD
Metoclopramide—CYP11B1—Metabolism—GNAS—peripheral nervous system neoplasm	0.000192	0.000884	CbGpPWpGaD
Metoclopramide—CYP11B1—Metabolism—ABCB1—peripheral nervous system neoplasm	0.000188	0.000867	CbGpPWpGaD
Metoclopramide—CYP17A1—Metabolism—GNAS—peripheral nervous system neoplasm	0.00018	0.000826	CbGpPWpGaD
Metoclopramide—DRD3—Circadian rythm related genes—TP53—peripheral nervous system neoplasm	0.00018	0.000826	CbGpPWpGaD
Metoclopramide—DRD2—Signaling Pathways—NTS—peripheral nervous system neoplasm	0.000177	0.000815	CbGpPWpGaD
Metoclopramide—HTR4—Signaling by GPCR—NRAS—peripheral nervous system neoplasm	0.000176	0.000811	CbGpPWpGaD
Metoclopramide—CYP17A1—Metabolism—ABCB1—peripheral nervous system neoplasm	0.000176	0.000811	CbGpPWpGaD
Metoclopramide—DRD3—Signaling by GPCR—KNG1—peripheral nervous system neoplasm	0.000176	0.00081	CbGpPWpGaD
Metoclopramide—DRD3—Signaling Pathways—VIP—peripheral nervous system neoplasm	0.000176	0.000807	CbGpPWpGaD
Metoclopramide—CHRM1—Signaling Pathways—NTS—peripheral nervous system neoplasm	0.000173	0.000798	CbGpPWpGaD
Metoclopramide—HTR4—Signaling Pathways—PTPN11—peripheral nervous system neoplasm	0.000173	0.000797	CbGpPWpGaD
Metoclopramide—CYP2D6—Metabolism—HSD17B12—peripheral nervous system neoplasm	0.000171	0.000787	CbGpPWpGaD
Metoclopramide—DRD2—Signaling Pathways—CD55—peripheral nervous system neoplasm	0.00017	0.000782	CbGpPWpGaD
Metoclopramide—DRD3—GPCR downstream signaling—GNAS—peripheral nervous system neoplasm	0.00017	0.00078	CbGpPWpGaD
Metoclopramide—CHRM1—Gastrin-CREB signalling pathway via PKC and MAPK—NRAS—peripheral nervous system neoplasm	0.000167	0.000766	CbGpPWpGaD
Metoclopramide—CHRM1—Signaling Pathways—CD55—peripheral nervous system neoplasm	0.000166	0.000765	CbGpPWpGaD
Metoclopramide—DRD3—Signaling Pathways—PPP3R1—peripheral nervous system neoplasm	0.000162	0.000745	CbGpPWpGaD
Metoclopramide—DRD3—Signaling by GPCR—GNAS—peripheral nervous system neoplasm	0.000154	0.000709	CbGpPWpGaD
Metoclopramide—DRD2—GPCR downstream signaling—KNG1—peripheral nervous system neoplasm	0.000148	0.000683	CbGpPWpGaD
Metoclopramide—CHRM1—GPCR downstream signaling—KNG1—peripheral nervous system neoplasm	0.000145	0.000668	CbGpPWpGaD
Metoclopramide—DRD2—Circadian rythm related genes—TP53—peripheral nervous system neoplasm	0.000137	0.000632	CbGpPWpGaD
Metoclopramide—HTR4—Signaling Pathways—ERBB2—peripheral nervous system neoplasm	0.000137	0.00063	CbGpPWpGaD
Metoclopramide—DRD2—Signaling by GPCR—KNG1—peripheral nervous system neoplasm	0.000135	0.00062	CbGpPWpGaD
Metoclopramide—CHRM1—Circadian rythm related genes—TP53—peripheral nervous system neoplasm	0.000134	0.000619	CbGpPWpGaD
Metoclopramide—DRD2—Signaling Pathways—VIP—peripheral nervous system neoplasm	0.000134	0.000618	CbGpPWpGaD
Metoclopramide—CHRM1—Signaling by GPCR—KNG1—peripheral nervous system neoplasm	0.000132	0.000607	CbGpPWpGaD
Metoclopramide—CHRM1—Signaling Pathways—VIP—peripheral nervous system neoplasm	0.000131	0.000605	CbGpPWpGaD
Metoclopramide—DRD2—GPCR downstream signaling—GNAS—peripheral nervous system neoplasm	0.00013	0.000597	CbGpPWpGaD
Metoclopramide—HTR4—Signaling by GPCR—HRAS—peripheral nervous system neoplasm	0.000129	0.000593	CbGpPWpGaD
Metoclopramide—CHRM1—GPCR downstream signaling—GNAS—peripheral nervous system neoplasm	0.000127	0.000584	CbGpPWpGaD
Metoclopramide—HTR4—GPCR downstream signaling—AKT1—peripheral nervous system neoplasm	0.000125	0.000577	CbGpPWpGaD
Metoclopramide—HTR4—Signaling Pathways—CASP3—peripheral nervous system neoplasm	0.000124	0.000572	CbGpPWpGaD
Metoclopramide—DRD2—Signaling Pathways—PPP3R1—peripheral nervous system neoplasm	0.000124	0.00057	CbGpPWpGaD
Metoclopramide—CYP2D6—Metabolism—GNS—peripheral nervous system neoplasm	0.000124	0.000569	CbGpPWpGaD
Metoclopramide—CHRM1—Gastrin-CREB signalling pathway via PKC and MAPK—HRAS—peripheral nervous system neoplasm	0.000122	0.000561	CbGpPWpGaD
Metoclopramide—DRD3—Signaling Pathways—NTRK2—peripheral nervous system neoplasm	0.000122	0.00056	CbGpPWpGaD
Metoclopramide—CHRM1—Signaling Pathways—PPP3R1—peripheral nervous system neoplasm	0.000121	0.000558	CbGpPWpGaD
Metoclopramide—CYP2D6—Metabolism—NME1—peripheral nervous system neoplasm	0.000119	0.000545	CbGpPWpGaD
Metoclopramide—DRD2—Signaling by GPCR—GNAS—peripheral nervous system neoplasm	0.000118	0.000542	CbGpPWpGaD
Metoclopramide—CHRM1—Signaling by GPCR—GNAS—peripheral nervous system neoplasm	0.000115	0.000531	CbGpPWpGaD
Metoclopramide—CYP2D6—Metabolism—COX2—peripheral nervous system neoplasm	0.000114	0.000525	CbGpPWpGaD
Metoclopramide—HTR4—Signaling by GPCR—AKT1—peripheral nervous system neoplasm	0.000114	0.000524	CbGpPWpGaD
Metoclopramide—DRD3—Signaling by GPCR—PTPN11—peripheral nervous system neoplasm	0.000107	0.000493	CbGpPWpGaD
Metoclopramide—HTR4—Signaling Pathways—NRAS—peripheral nervous system neoplasm	0.000104	0.000479	CbGpPWpGaD
Metoclopramide—DRD3—Signaling Pathways—KNG1—peripheral nervous system neoplasm	0.000104	0.000479	CbGpPWpGaD
Metoclopramide—DRD3—Signaling Pathways—NTRK1—peripheral nervous system neoplasm	9.92e-05	0.000456	CbGpPWpGaD
Metoclopramide—HTR4—Signaling Pathways—MYC—peripheral nervous system neoplasm	9.7e-05	0.000446	CbGpPWpGaD
Metoclopramide—DRD2—Signaling Pathways—NTRK2—peripheral nervous system neoplasm	9.31e-05	0.000428	CbGpPWpGaD
Metoclopramide—CHRM1—Signaling Pathways—NTRK2—peripheral nervous system neoplasm	9.11e-05	0.000419	CbGpPWpGaD
Metoclopramide—DRD3—Signaling Pathways—GNAS—peripheral nervous system neoplasm	9.1e-05	0.000419	CbGpPWpGaD
Metoclopramide—DRD2—Signaling by GPCR—PTPN11—peripheral nervous system neoplasm	8.19e-05	0.000377	CbGpPWpGaD
Metoclopramide—CHRM1—Signaling by GPCR—PTPN11—peripheral nervous system neoplasm	8.02e-05	0.000369	CbGpPWpGaD
Metoclopramide—HTR4—Signaling Pathways—TP53—peripheral nervous system neoplasm	7.97e-05	0.000366	CbGpPWpGaD
Metoclopramide—DRD2—Signaling Pathways—KNG1—peripheral nervous system neoplasm	7.96e-05	0.000366	CbGpPWpGaD
Metoclopramide—CHRM1—Signaling Pathways—KNG1—peripheral nervous system neoplasm	7.79e-05	0.000359	CbGpPWpGaD
Metoclopramide—HTR4—Signaling Pathways—HRAS—peripheral nervous system neoplasm	7.62e-05	0.00035	CbGpPWpGaD
Metoclopramide—DRD2—Signaling Pathways—NTRK1—peripheral nervous system neoplasm	7.59e-05	0.000349	CbGpPWpGaD
Metoclopramide—CYP2D6—Metabolism—ENO2—peripheral nervous system neoplasm	7.49e-05	0.000345	CbGpPWpGaD
Metoclopramide—CHRM1—Signaling Pathways—NTRK1—peripheral nervous system neoplasm	7.43e-05	0.000342	CbGpPWpGaD
Metoclopramide—DRD2—Signaling Pathways—GNAS—peripheral nervous system neoplasm	6.96e-05	0.00032	CbGpPWpGaD
Metoclopramide—CHRM1—Signaling Pathways—GNAS—peripheral nervous system neoplasm	6.82e-05	0.000314	CbGpPWpGaD
Metoclopramide—HTR4—Signaling Pathways—AKT1—peripheral nervous system neoplasm	6.73e-05	0.000309	CbGpPWpGaD
Metoclopramide—DRD3—Signaling by GPCR—NRAS—peripheral nervous system neoplasm	6.44e-05	0.000296	CbGpPWpGaD
Metoclopramide—CYP2D6—Metabolism—BCHE—peripheral nervous system neoplasm	6.33e-05	0.000291	CbGpPWpGaD
Metoclopramide—DRD3—Signaling Pathways—PTPN11—peripheral nervous system neoplasm	6.32e-05	0.000291	CbGpPWpGaD
Metoclopramide—CYP2D6—Metabolism—SLC2A1—peripheral nervous system neoplasm	6.04e-05	0.000278	CbGpPWpGaD
Metoclopramide—CYP11B2—Metabolism—AKT1—peripheral nervous system neoplasm	6.02e-05	0.000277	CbGpPWpGaD
Metoclopramide—CYP2D6—Metabolism—TH—peripheral nervous system neoplasm	5.95e-05	0.000274	CbGpPWpGaD
Metoclopramide—CYP11B1—Metabolism—AKT1—peripheral nervous system neoplasm	5.18e-05	0.000238	CbGpPWpGaD
Metoclopramide—DRD3—Signaling Pathways—ERBB2—peripheral nervous system neoplasm	5e-05	0.00023	CbGpPWpGaD
Metoclopramide—DRD2—Signaling by GPCR—NRAS—peripheral nervous system neoplasm	4.93e-05	0.000227	CbGpPWpGaD
Metoclopramide—CYP2D6—Metabolism—GNAS—peripheral nervous system neoplasm	4.86e-05	0.000223	CbGpPWpGaD
Metoclopramide—CYP17A1—Metabolism—AKT1—peripheral nervous system neoplasm	4.85e-05	0.000223	CbGpPWpGaD
Metoclopramide—DRD2—Signaling Pathways—PTPN11—peripheral nervous system neoplasm	4.84e-05	0.000223	CbGpPWpGaD
Metoclopramide—CHRM1—Signaling by GPCR—NRAS—peripheral nervous system neoplasm	4.82e-05	0.000222	CbGpPWpGaD
Metoclopramide—CYP2D6—Metabolism—ABCB1—peripheral nervous system neoplasm	4.77e-05	0.000219	CbGpPWpGaD
Metoclopramide—CHRM1—Signaling Pathways—PTPN11—peripheral nervous system neoplasm	4.74e-05	0.000218	CbGpPWpGaD
Metoclopramide—DRD3—Signaling by GPCR—HRAS—peripheral nervous system neoplasm	4.71e-05	0.000217	CbGpPWpGaD
Metoclopramide—DRD3—GPCR downstream signaling—AKT1—peripheral nervous system neoplasm	4.58e-05	0.000211	CbGpPWpGaD
Metoclopramide—DRD3—Signaling Pathways—CASP3—peripheral nervous system neoplasm	4.54e-05	0.000209	CbGpPWpGaD
Metoclopramide—DRD3—Signaling by GPCR—AKT1—peripheral nervous system neoplasm	4.16e-05	0.000191	CbGpPWpGaD
Metoclopramide—DRD2—Signaling Pathways—ERBB2—peripheral nervous system neoplasm	3.82e-05	0.000176	CbGpPWpGaD
Metoclopramide—DRD3—Signaling Pathways—NRAS—peripheral nervous system neoplasm	3.8e-05	0.000175	CbGpPWpGaD
Metoclopramide—CHRM1—Signaling Pathways—ERBB2—peripheral nervous system neoplasm	3.74e-05	0.000172	CbGpPWpGaD
Metoclopramide—DRD2—Signaling by GPCR—HRAS—peripheral nervous system neoplasm	3.6e-05	0.000166	CbGpPWpGaD
Metoclopramide—DRD3—Signaling Pathways—MYC—peripheral nervous system neoplasm	3.54e-05	0.000163	CbGpPWpGaD
Metoclopramide—CHRM1—Signaling by GPCR—HRAS—peripheral nervous system neoplasm	3.53e-05	0.000162	CbGpPWpGaD
Metoclopramide—DRD2—GPCR downstream signaling—AKT1—peripheral nervous system neoplasm	3.5e-05	0.000161	CbGpPWpGaD
Metoclopramide—DRD2—Signaling Pathways—CASP3—peripheral nervous system neoplasm	3.47e-05	0.00016	CbGpPWpGaD
Metoclopramide—CHRM1—GPCR downstream signaling—AKT1—peripheral nervous system neoplasm	3.43e-05	0.000158	CbGpPWpGaD
Metoclopramide—CHRM1—Signaling Pathways—CASP3—peripheral nervous system neoplasm	3.4e-05	0.000156	CbGpPWpGaD
Metoclopramide—DRD2—Signaling by GPCR—AKT1—peripheral nervous system neoplasm	3.18e-05	0.000146	CbGpPWpGaD
Metoclopramide—CHRM1—Signaling by GPCR—AKT1—peripheral nervous system neoplasm	3.11e-05	0.000143	CbGpPWpGaD
Metoclopramide—DRD2—Signaling Pathways—NRAS—peripheral nervous system neoplasm	2.91e-05	0.000134	CbGpPWpGaD
Metoclopramide—DRD3—Signaling Pathways—TP53—peripheral nervous system neoplasm	2.91e-05	0.000134	CbGpPWpGaD
Metoclopramide—CHRM1—Signaling Pathways—NRAS—peripheral nervous system neoplasm	2.85e-05	0.000131	CbGpPWpGaD
Metoclopramide—DRD3—Signaling Pathways—HRAS—peripheral nervous system neoplasm	2.78e-05	0.000128	CbGpPWpGaD
Metoclopramide—DRD2—Signaling Pathways—MYC—peripheral nervous system neoplasm	2.71e-05	0.000125	CbGpPWpGaD
Metoclopramide—CHRM1—Signaling Pathways—MYC—peripheral nervous system neoplasm	2.65e-05	0.000122	CbGpPWpGaD
Metoclopramide—DRD3—Signaling Pathways—AKT1—peripheral nervous system neoplasm	2.46e-05	0.000113	CbGpPWpGaD
Metoclopramide—DRD2—Signaling Pathways—TP53—peripheral nervous system neoplasm	2.23e-05	0.000102	CbGpPWpGaD
Metoclopramide—CHRM1—Signaling Pathways—TP53—peripheral nervous system neoplasm	2.18e-05	0.0001	CbGpPWpGaD
Metoclopramide—DRD2—Signaling Pathways—HRAS—peripheral nervous system neoplasm	2.13e-05	9.79e-05	CbGpPWpGaD
Metoclopramide—CHRM1—Signaling Pathways—HRAS—peripheral nervous system neoplasm	2.08e-05	9.58e-05	CbGpPWpGaD
Metoclopramide—DRD2—Signaling Pathways—AKT1—peripheral nervous system neoplasm	1.88e-05	8.65e-05	CbGpPWpGaD
Metoclopramide—CHRM1—Signaling Pathways—AKT1—peripheral nervous system neoplasm	1.84e-05	8.46e-05	CbGpPWpGaD
Metoclopramide—CYP2D6—Metabolism—AKT1—peripheral nervous system neoplasm	1.31e-05	6.03e-05	CbGpPWpGaD
